Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RORC | P51449 | 7/20 | 0.53 |
| ▸ | DGAT2 | Q96PD7 | 10/20 | 0.52 |
| ▸ | RARG | P13631 | 3/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL348428 | 0.91 | DGAT2 (0.62) | MEN1KMT2ADGAT2 | |
| SCHEMBL346686 | 0.88 | DGAT2 (0.56) | MEN1KMT2ADGAT2 | |
| SCHEMBL20166434 | 0.80 | DGAT2 (0.73) | DGAT2 | |
| SCHEMBL346584 | 0.80 | DGAT2 (0.65) | DGAT2 | |
| SCHEMBL348115 | 0.78 | DGAT2 (0.67) | DGAT2 | |
| SCHEMBL13187394 | 0.76 | DGAT2 (0.52) | DGAT2 | |
| SCHEMBL730542 | 0.74 | HTT (0.58) | MEN1KMT2ARORCRARG | |
| SCHEMBL347945 | 0.73 | DGAT2 (0.54) | MEN1KMT2ARORCDGAT2 | |
| SCHEMBL20166461 | 0.73 | DGAT2 (0.53) | DGAT2 | |
| SCHEMBL4486680 | 0.72 | KMT2A (1.00) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411001-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2018-01-17 | — | — | EP | disclosed |
| US-8569512-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2411001-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | Merck Sharp & Dohme Corp. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME LLC | 2012-01-19 | — | — | US | disclosed |
| WO-2010111060-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015052-A1 | P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | MEN1 4860/4885KMT2A 4191/4885RORC 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.